Dhasmana K M, Villalón C M, Zhu Y N, Parmar S S
Department of Anaesthesiology, Faculty of Medicine and Health Sciences, Erasmus University Rotterdam, The Netherlands.
Pharmacol Res. 1993 May-Jun;27(4):335-47. doi: 10.1006/phrs.1993.1033.
This study analyses the effects of dopamine receptor agonists and antagonists on rat gastrointestinal transit (GIT) in an attempt to identify the mechanisms involved. Dopamine (DA), apomorphine, quinpirole, bromocriptine and fenoldopam were given by subcutaneous (s.c.), intrathecal (i.t.), intracisternal (i.c.) and/or intraperitoneal (i.p.) routes. In general, DA (200 micrograms, i.t.), apomorphine (3, 5 and 10 mg/kg, s.c.; or 10, 30 and 100 micrograms, i.t.), and bromocriptine (1, 5 and 10 mg/kg, s.c.) elicited decreases in gastrointestinal transit which were significantly antagonized by the D2 receptor antagonists domperidone or alizapride (both 5 mg/kg, s.c.), but remained unaffected by the D1 receptor antagonist SCH 23390 (5 mg/kg, s.c.). Similarly, DA (50, 100 and 200 micrograms, i.c.) and apomorphine (12 and 50 micrograms; i.c.) produced dose-dependent decreases in gastrointestinal transit amenable to blockade by the classical DA receptor antagonist haloperidol (10 micrograms, i.c.). The responses to apomorphine (3, 5 and 10 mg/kg, s.c.) were unaltered by 6-hydroxydopamine (100 mg/kg, i.p.)-induced sympathectomy but were antagonized by both propranolol (1 mg/kg, s.c.) and phentolamine (5 mg/kg, s.c.). Significantly, after bilateral (cervical) vagotomy, gastrointestinal transit was markedly reduced, but apomorphine (5 mg/kg, s.c.) apparently further reduced gastrointestinal transit. The D1 agonists fenoldopam (5, 10 and 20 mg/kg, s.c.) significantly reduced GIT. Fenoldopam-induced antitransit effects were markedly modified by the D1 receptor antagonist, SCH 23390 (5 mg/kg, s.c.); only the response induced by 5 mg/kg of fenoldopam was apparently antagonized by SCH 23390. The mixed D2 and D3 receptor agonist quinpirole (4 and 8 mg/kg, s.c.; or 8 mg/kg, i.p.; 200 micrograms, i.t.) did mimic DA eliciting significant reductions in gastrointestinal transit which, however, were not antagonized by domperidone (5 mg/kg, s.c.). Taken together, the present results support the contention that the decrease in rat gastrointestinal transit induced by DA and apomorphine may be mediated by an interaction with central and/or peripheral D2 receptors. The presence of dopamine receptors (D2) in the alimentary canal are strengthened by antitransit effect of fenoldopam and bromocriptine in the gastrointestinal tract.
本研究分析了多巴胺受体激动剂和拮抗剂对大鼠胃肠转运(GIT)的影响,以试图确定其中涉及的机制。多巴胺(DA)、阿扑吗啡、喹吡罗、溴隐亭和非诺多泮通过皮下(s.c.)、鞘内(i.t.)、脑池内(i.c.)和/或腹腔内(i.p.)途径给药。一般来说,DA(200微克,鞘内注射)、阿扑吗啡(3、5和10毫克/千克,皮下注射;或10、30和100微克,鞘内注射)以及溴隐亭(1、5和10毫克/千克,皮下注射)引起胃肠转运降低,D2受体拮抗剂多潘立酮或阿立必利(均为5毫克/千克,皮下注射)可显著拮抗这种降低,但D1受体拮抗剂SCH 23390(5毫克/千克,皮下注射)对其无影响。同样,DA(50、100和200微克,脑池内注射)和阿扑吗啡(12和50微克;脑池内注射)产生剂量依赖性的胃肠转运降低,经典的DA受体拮抗剂氟哌啶醇(10微克,脑池内注射)可阻断这种降低。对阿扑吗啡(3、5和10毫克/千克,皮下注射)的反应不受6-羟基多巴胺(100毫克/千克,腹腔内注射)诱导的交感神经切除术影响,但可被普萘洛尔(1毫克/千克,皮下注射)和酚妥拉明(5毫克/千克,皮下注射)拮抗。值得注意的是,双侧(颈)迷走神经切断术后,胃肠转运明显降低,但阿扑吗啡(5毫克/千克,皮下注射)显然进一步降低了胃肠转运。D1激动剂非诺多泮(5、10和20毫克/千克,皮下注射)显著降低了胃肠转运。非诺多泮诱导的抗转运作用被D1受体拮抗剂SCH 23390(5毫克/千克,皮下注射)显著改变;只有5毫克/千克非诺多泮诱导的反应明显被SCH 23390拮抗。混合的D2和D3受体激动剂喹吡罗(4和8毫克/千克,皮下注射;或8毫克/千克,腹腔内注射;200微克,鞘内注射)确实模拟了DA引起的胃肠转运显著降低,然而,这种降低未被多潘立酮(5毫克/千克,皮下注射)拮抗。综上所述,目前的结果支持这样的观点,即DA和阿扑吗啡诱导的大鼠胃肠转运降低可能是通过与中枢和/或外周D2受体相互作用介导的。消化道中多巴胺受体(D2)的存在通过非诺多泮和溴隐亭在胃肠道中的抗转运作用得到加强。